Requiem For Cures 2.0: An Idea Whose Time Has Come, But Will Still Have To Wait
Executive Summary
The Upton-DeGette legislation wasn’t going to be part of the omnibus bill moving through Congress this week, but its original concepts – creating more clarity on CMS reimbursement – seem as critical as ever.
You may also be interested in...
Donanemab In Medicare: Quick Reversal Of Alzheimer’s Coverage Limits Doubtful, Lilly Says
Lilly execs caution that even if FDA approves donanemab in 2023, no uptake of any significance is expected until 2024 and beyond. An accelerated approval would essentially preclude Medicare reimbursement, and a CMS policy change or more persuasive trial data could take some time.
CMS Building Rx Price Negotiating Staff Internally; Contracting With Outside Groups ‘Not On Radar’
CMS head Brooks-LaSure says agency is making progress in staffing the drug pricing control programs established by the Inflation Reduction Act. Medicare Center deputy director Cheri Rice will be its acting director under just-unveiled management structure.
As US House Changes Hands, CMS May Face More Oversight Than FDA
Key Republican committee chairs on health issues are familiar faces, largely supportive of the US FDA’s approach to drug regulation. Implementation of the new pricing law, however, will get a lot more scrutiny.